Department of Biotechnology, University of Turku, Tykistökatu 6A, 20520 Turku, Finland.
Clin Biochem. 2012 May;45(7-8):535-40. doi: 10.1016/j.clinbiochem.2012.02.012. Epub 2012 Feb 27.
To investigate the predictive value of cystatin C among patients diagnosed with non-ST-elevation acute coronary syndrome (nSTE-ACS).
Admission serum samples from 245 nSTE-ACS patients were measured with a novel cystatin C immunoassay based on a dry-reagent, double monoclonal design. Creatinine concentrations, estimated glomerular filtration rates (eGFR) and one-year follow-up data were available for these patients.
During the follow-up period, 34 (14%) of patients had myocardial infarction (MI) and 25 (11%) died. Increased serum cystatin C was an independent predictor of all-cause mortality and combined events (all-cause mortality and MI) after adjustment to non-biomarker baseline factors, hazard ratio (HR) 2.19 (per increase of 1 tertile; 95% Cl 1.28-3.78, p=0.0046) and 1.75 (1.22-2.51, p=0.0024), respectively. Corresponding values for eGFR were 2.56 (1.43-4.59, p=0.0016) and 1.76 (1.23-2.53, p=0.0022), respectively. Creatinine was not an independent predictor of endpoints (p>0.05).
Cystatin C was associated with an increased risk of death and combined events in patients with nSTE-ACS.
研究胱抑素 C 对非 ST 段抬高型急性冠状动脉综合征（nSTE-ACS）患者的预测价值。
采用新型基于干试剂、双单克隆设计的胱抑素 C 免疫测定法，检测 245 名 nSTE-ACS 患者入院时的血清样本。这些患者有肌酐浓度、估算肾小球滤过率（eGFR）和一年随访数据。
在随访期间，34 名（14%）患者发生心肌梗死（MI），25 名（11%）患者死亡。校正非生物标志物基线因素后，血清胱抑素 C 升高是全因死亡率和复合事件（全因死亡率和 MI）的独立预测因素，风险比（HR）分别为 2.19（每增加 1 个 tertile；95%Cl 1.28-3.78，p=0.0046）和 1.75（1.22-2.51，p=0.0024）。eGFR 的相应值分别为 2.56（1.43-4.59，p=0.0016）和 1.76（1.23-2.53，p=0.0022）。肌酐不是终点的独立预测因素（p>0.05）。
胱抑素 C 与 nSTE-ACS 患者的死亡和复合事件风险增加相关。
